Genmab A/S (GMAB) Opens U.S. Hub in New Jersey to Drive Global Growth
Genmab A/S (NASDAQ:GMAB), a Danish biotech company founded in 1999, specializes in antibody-based therapies for cancer and serious diseases. Known for its technologies like HuMab-Mouse and UniBody, the corporation has historically partnered with major pharmaceutical companies such as Johnson & Johnson and AbbVie to bring its innovations to market. However, the company is now undergoing a strategic transformation to become a fully integrated global commercial entity.
In June 2025, Genmab A/S (NASDAQ:GMAB) opened a major new U.S. site in Plainsboro, New Jersey, signaling a shift from a partnership-driven model to direct commercialization of its therapies. This move gives the company greater control over its innovation, regulatory processes, and patient outreach, aligning with a broader biotech industry trend toward independence and vertical integration.
The business's oncology portfolio continues to gain traction. Tivdak (cervical cancer) received full FDA approval in April 2024, while Epkinly (lymphoma), which earned accelerated approval in 2023, has shown strong sales growth in the U.S. Genmab A/S (NASDAQ:GMAB)'s pipeline also remains active, with ongoing development of therapies like Epcoritamab and Acasunlimab. At the June 2025 ASCO meeting, the company presented promising Rina-S data, supporting an upcoming Phase III trial.
A healthcare professional wearing a health communications device discussing patient data with a colleague.
The corporation continues to benefit from its successful collaboration with Johnson & Johnson on DARZALEX, which remains a significant revenue driver. The company is also focused on long-term growth by investing in talent retention through stock-based incentives.
While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Weather Shocks vs. Oversupply: Are You Trading SRW Wheat's Next Big Move?
The 2025/26 marketing year, June 01 to May 31, for Chicago Soft Red Winter (SRW) wheat shows a mixed supply and demand picture, with harvest occurring from late May to August, primarily in the U.S. South, Great Lakes, and Atlantic regions. The USDA's Economic Research Service projects that U.S. wheat ending stocks for 2025/26 will be the highest since 2019/20, up 10% from 2024/25, driven by larger beginning stocks. U.S. wheat exports are projected to be down by 20 million bushels, constrained by larger projected exports from competitors like the EU, Argentina, and Russia. Demand remains steady but faces headwinds from global competition, as SRW is the world's cheapest wheat, with funds holding net short positions since 2022. This competitive pricing stems from robust U.S. production and improved moisture conditions as crops enter the heading phase, which could keep prices subdued. Speculators should note the potential for volatility tied to inter-market spreads with other grains, while hedgers must monitor export demand and global stock levels to manage risk effectively. The latest crop progress report indicates that the U.S. winter wheat harvest is 63% complete, slightly behind the 5-year average. Spring wheat is 78% headed, exceeding the average by 3%. The good to excellent condition rating for spring wheat increased by 4% to 54%, with notable improvements in Minnesota, Montana, North Dakota, and South Dakota. This abundance, especially in SRW, could flood the market and cause depressed prices. More News from Barchart Warren Buffett Warns Inflation Turns Business Into 'The Upside-Down World of Alice in Wonderland' But Weeds Out 'Bad Businesses' Why GOOGL Stock May Be the Market's Next Big Winner Alphabet Posts Lower Free Cash Flow and FCF Margins - Is GOOGL Stock Overvalued? Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! A positive event supporting higher prices is continuing weather disruptions in regions like Southern Russia, Ukraine, or Northern Europe, where dryness and frost risks persist. Such events could tighten global supply, boosting SRW demand as a cost-competitive alternative. The wheat market outlook remains cautious for the upcoming season, with prices likely to stay range-bound to lower unless significant weather shocks disrupt supply. Speculators might find opportunities in short-term weather-driven rallies. At the same time, hedgers may consider locking in prices during potential spikes, given the bearish bias from ample U.S. stocks and global competition. Technical Picture Source: Barchart Since the recent peak in February 2025, the 50 simple moving average (SMA) has contained the short-lived price rallies. Price action appears to be trading sideways, but the SMA is still sloping down. The market will be keeping an eye on the 543'6 low from May. The Commitment of Traders (COT) Report Source: CME Group Exchange The managed money traders' COT report shows aggressive selling(red lines) and remaining net short (yellow line) since July 2022. They hold 31% of open short positions, a slight increase from three months ago. Source: Barchart The continuous weekly nearest contract wheat chart shows the price action since managed money traders went net short in 2022 and have remained with that sentiment. The wheat market has been holding support at the 506'0 to 514'0 level. However, the rallies from these levels appear weaker with each attempt failing to get any traction or sentiment change from the trend-following managed money traders. Seasonal Pattern Source: Moore Research Center, Inc. (MRCI) MRCI seasonal research often finds patterns tied to the expiration or delivery of a futures contract. The upcoming seasonal window (yellow box) correlates to the September wheat contract's First Notice Day (FND), as prices historically have declined into this period. The reasons may be the convergence of the futures to spot prices at expiration, storage, and carry cost, as the premium may erode as expiration approaches, or just the new supply coming to the latest market year that started in June. With the technical picture showing weak levels off of the May lows and the bearish sentiment remaining in the managed money traders' camp, the upcoming seasonal sell may be the catalyst to lower prices. Source: MRCI MRCI research has found that over the past 15 years, the December wheat contract has closed lower on approximately September 01 than on August 05 for 13 years, with an 87% occurrence rate. In addition, three of the years never had a daily closing drawdown. Based on hypothetical testing, the average net profit has been 24 cents or $1,204 per standard-sized 5,000 bushel wheat contract. As a crucial reminder, while seasonal patterns can provide valuable insights, they should not be the basis for trading decisions. Traders must consider various technical and fundamental indicators, risk management strategies, and market conditions to make informed and balanced trading decisions. Assets to Trade the Wheat Market Wheat futures are traded on the CME Group Exchange: The standard-size contract (ZW) and the mini-size contract (XW). Options on the wheat futures at the CME Group Exchange are also available. Equity traders may find that the exchange-traded fund (ETF) (WEAT) offers opportunities in their equity accounts without opening futures trading accounts. In Closing….. The 2025/26 marketing year for Chicago Soft Red Winter (SRW) wheat, spanning June 01 to May 31, presents a complex supply and demand landscape for speculators and hedgers. Harvested from late May to August across the U.S. South, Great Lakes, and Atlantic regions, SRW faces bearish pressures from a projected 10% increase in U.S. wheat ending stocks, the highest since 2019/20, driven by robust production and larger beginning stocks, according to the USDA. Global competition from the EU, Argentina, and Russia caps U.S. exports, down 20 million bushels. At the same time, SRW's position as the world's cheapest wheat fuels record net short positions by managed money traders since 2022. Improved crop conditions, with 54% of spring wheat rated good-to-excellent and the U.S. winter wheat harvest 63% complete, signal an ample supply that could depress prices further. However, weather disruptions in Southern Russia, Ukraine, or Northern Europe could tighten global supply, potentially lifting SRW demand and prices. The market's technical picture underscores bearish sentiment, with prices trading sideways below a declining 50 SMA and weak rallies off the 506'0–514'0 support. Seasonal patterns add another layer, with Moore Research Center (MRCI) data indicating an 87% chance of December wheat futures closing lower by September 01 compared to August 05, possibly driven by annual futures-to-spot convergence, storage costs, and new supply. The Commitment of Traders report confirms managed money traders' aggressive selling, holding 31% of open short positions, reinforcing a bearish outlook. Speculators can target short-term weather-driven rallies, while hedgers should lock prices during potential spikes to manage downside risk. The challenge is clear: Will you act on the bearish seasonal window and technical weakness, or wait for a weather shock to shift sentiment? Use assets like CME wheat futures (ZW, XW), options, or the WEAT ETF to position strategically, but don't rely solely on seasonal patterns—integrate technicals, fundamentals, and risk management to navigate this volatile market. On the date of publication, Don Dawson did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
Yahoo
25 minutes ago
- Yahoo
2 Top Dividend Stocks to Buy Right Now and Hold Forever
Key Points Amgen can replenish its lineup thanks to a deep pipeline. AbbVie has a knack for getting around headwinds. Both drugmakers have strong dividend track records. 10 stocks we like better than Amgen › Over the long run, dividends can make a significant difference in your returns, whether you choose to reinvest the payouts or retain the cash for other purposes. However, many companies that offer dividends aren't exactly attractive to hold on to for a long time. Some have somewhat shaky underlying operations, and others are not inclined to regularly raise their dividends. Thankfully, some income stocks on the market don't have these issues, and their shares are worth holding on to forever. Let's consider two examples: Amgen (NASDAQ: AMGN) and AbbVie (NYSE: ABBV). 1. Amgen If you're an income-seeking investor, Amgen has several qualities that you'll appreciate. First, it's a leader in healthcare, a defensive industry. The demand for the medicines that the company develops -- some of which are lifesaving -- won't stop even during economic downturns, nor will physicians stop prescribing them. Amgen is well equipped to perform regardless of economic conditions. The drugmaker generates consistent revenue and earnings. Second, it continues to innovate. True, it has encountered clinical setbacks of late; its investigational weight management medicine, MariTide, didn't perform as well in mid-stage studies as expected. However, the company recently reported phase 3 results for bemarituzumab, a medicine it's developing for gastric cancer, the fifth leading cause of cancer death worldwide. This product now appears likely to secure regulatory approval and make a meaningful contribution to Amgen's results for a while. The company will continue to face competition and patent cliffs, but it's been able to perform well over the long run despite these challenges, thanks to its innovative abilities. Amgen can also rely on licensing deals and acquisitions to bolster its lineup and pipeline. In 2023, it acquired Horizon Therapeutics and its medicine for thyroid eye disease, Tepezza, for about $28 billion. Amgen has been able to push Tepezza's reach far beyond what the smaller Horizon would have been able to accomplish; it earned approval for the medicines in countries like Japan and Brazil, while pouring money into advertising and marketing efforts. Third, Amgen has a strong track record of dividend payments. The biotech initiated a payout in 2011, and since then, it's increased its dividends every single year. It currently offers a forward yield of 3.1%, considerably higher than the S&P 500's average of 1.3%. And the cash payout ratio of 46.5% appears reasonable, leaving ample room for further payout increases. Amgen's ability to develop novel lifesaving medicines, its consistent financial results, and its regular payout increases make it a top dividend stock to buy and hold for the long term. 2. AbbVie Although AbbVie has lagged behind the market over the past three years, this period highlights the company's resilient qualities. After losing patent exclusivity in January 2023 for Humira, an immunology medicine that was its best-selling drug and also the most lucrative in the industry's history, management predicted that the company would return to top-line growth in 2025. AbbVie resumed revenue growth last year, ahead of schedule. It's not rare for drugmakers to go through several years of declining revenue following a major patent cliff, nor is it necessarily a cause for concern. AbbVie's ability to bounce back as quickly as it did speaks volumes about the strength of its underlying business, its ability to navigate competition -- biosimilar and otherwise -- and its long-term prospects. True, the company encountered a significant setback when a seemingly promising candidate for schizophrenia called emraclidine, which it had gotten its hands on through an acquisition, failed mid-stage studies. AbbVie has faced similar problems before and has bounced back. The company had bet on a cancer medicine called Rova-T to be a significant growth driver post-Keytruda. However, this medicine failed in the clinic. Instead, AbbVie is now relying on Skyrizi and Rinvoq, two immunosuppressants, to drive top-line growth. These medicines have surpassed its own expectations, and they should continue to be significant contributors for years to come. The company has consistently found ways to overcome setbacks and challenges. Its financial results remain robust; the pipeline is deep; the balance sheet is strong. And its dividend track record is outstanding: AbbVie is a Dividend King, boasting 53 consecutive years of payout increases. Its forward yield now tops 3.4%, while the cash payout ratio of 61.8% is still reasonable. This is another dividend stock that you could safely include in a long-term portfolio. Should you invest $1,000 in Amgen right now? Before you buy stock in Amgen, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Amgen wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 28, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie and Amgen. The Motley Fool has a disclosure policy. 2 Top Dividend Stocks to Buy Right Now and Hold Forever was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
Lincoln National Corporation (LNC) Secures $825M Investment from Bain Capital
We recently compiled a list of Lincoln National Corporation stands third on our list and has recently secured $825 million investment from Bain Capital. Lincoln National Corporation (NYSE:LNC), a leading U.S. provider of insurance and retirement solutions, is advancing its strategy in 2025 through a major partnership with Bain Capital. In April, Bain Capital acquired a 9.9% stake in the business for $825 million, marking a significant move toward optimizing Lincoln National Corporation (NYSE:LNC)'s investment and growth strategies. As part of the deal, Bain Capital will manage assets across private credit, structured assets, mortgage loans, and private equity for the corporation over 10 years. This collaboration supports the company's goal of accessing high-quality private assets with attractive, risk-adjusted returns, enhancing its multi-manager platform, and driving growth in spread-based earnings. To fund this partnership, Lincoln National Corporation (NYSE:LNC) will sell approximately 18.8 million shares at $44 each, a 25% premium over the prior 30-day average, offering the company greater financial flexibility to invest in innovation, reduce leverage, and pursue strategic goals. 15 States with the Cheapest Home Insurance in the US CEO Ellen Cooper called the partnership a 'pivotal milestone,' highlighting the alignment of values and long-term vision between the firms. This move also reflects a broader industry shift, as insurers increasingly turn to alternative asset classes to improve yield and manage risk in a challenging interest rate environment. While we acknowledge the potential of LNC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
